Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01247571 · OUTCOME

Percentage of Participants With Progression-free Survival (PFS) at 6 Months

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
6 months

What was measured

Progression-free survival is the period from study entry until disease progression, death or date of last contact. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Analysis population: Eligible and treated patients

Groups in this outcome

Pazopanib

Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib19

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Pazopanib15.8Not reported4.435.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.4
        upper Limit
        35.9
        value
        15.8
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
Progression-free survival is the period from study entry until disease progression, death or date of last contact. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
dispersion Type
90% Confidence Interval
groups
  1. description
    Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
    id
    OG000
    title
    Pazopanib
param Type
NUMBER
population Description
Eligible and treated patients
reporting Status
POSTED
time Frame
6 months
title
Percentage of Participants With Progression-free Survival (PFS) at 6 Months
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice